Why Is Nasus Pharma Stock Up Today?
The FDA cleared Nasus Pharma's IND for NS002, its nasal epinephrine powder for anaphylaxis, ahead of a pivotal study planned for the fourth quarter of 2026. The stock was up 10.13% at 12:24 ET.
- The FDA cleared Nasus Pharma's IND for NS002, a needle-free nasal epinephrine powder for anaphylaxis.
- Nasus plans a pivotal study in the fourth quarter of 2026 and topline data in the first quarter of 2027.
- Cash of $11.9 million at June 30 funds operations through the second quarter of 2027, one quarter after the planned readout.
Reaction by asset (real prices)
| Asset | 2m before | At release | +1m | +session | +1m % | +session % |
|---|---|---|---|---|---|---|
| NSRX | 3.63 | 3.63 | 3.63 | 3.20 | 0.00% | -11.85% |
Nasus Pharma stock is up today after the FDA cleared the company's Investigational New Drug application for NS002, a needle-free epinephrine powder sprayed into the nose to treat anaphylaxis, and Nasus restated its plan to start a pivotal study in the fourth quarter of 2026 with topline data in the first quarter of 2027. At 12:24 ET the stock traded at $3.75, up 10.13% from Friday's close of $3.40.
What the FDA cleared
The IND clearance allows Nasus to start a clinical study of NS002 as a needle-free alternative to EpiPen, including a comparison of patients giving themselves the dose with a health care professional giving it. The pivotal study is a separate trial that Nasus plans to begin in the fourth quarter of 2026, and the company expects its topline readout to support a potential New Drug Application.
The case for NS002 rests on speed. In Nasus's Phase 2 study, NS002 reached the 100 pg/mL plasma epinephrine threshold in a median of 1.69 minutes, against 3.47 minutes for EpiPen. Nasus estimates the anaphylaxis market at about $2 billion.
How long the cash lasts
| First half 2026 | First half 2025 | |
|---|---|---|
| Net loss | $5.9 million | $1.3 million |
| Research and development | $2.6 million | $0.3 million |
Nasus had $11.9 million in cash, cash equivalents and short-term deposits at June 30, 2026, up from $4.3 million at the end of 2025 after a private placement of shares and warrants that raised about $15.0 million gross. The company said that cash funds operations through the second quarter of 2027. That is one quarter after the planned pivotal readout, and spending is climbing as NS002 moves forward: research and development costs in the first half were more than eight times the year before.
Why the measured reaction and the session move point different ways
The pivotal-study line crossed MoveSurge's tape at 08:10:53 ET, a few minutes after the first clearance headline at 08:07:07 ET. MoveSurge measured the stock 11.846% lower ten minutes later, at $3.20 against a reference of $3.63. That reference was the last trade on record, 6.61% above Friday's close, and no shares changed hands for several minutes after the release. The first premarket trades were $3.40 at 08:16 (100 shares), $3.27 at 08:17 (144 shares), $3.20 at 08:20 (108 shares), 352 shares in all. Measured from Friday's close, the $3.20 print was 6.02% lower. By 12:24 ET the stock was up 10.13% from that close.
Nasus Pharma timeline
- August 13, 2025 — shares began trading on NYSE American after an initial public offering of 1,250,000 shares at $8.00, raising $10 million gross.
- March 25, 2026 — annual results; Nasus said it was moving NS002 toward a pivotal study after a positive Phase 2.
- August 17, 2026 — first-half results: $11.9 million in cash at June 30 and a runway through the second quarter of 2027.
- September 14, 2026 — FDA clears the NS002 IND.
- Fourth quarter of 2026 — planned start of the pivotal study.
- First quarter of 2027 — planned topline data.
At 12:24 ET the stock was 53.13% below its $8.00 IPO price.
Why is Nasus Pharma stock up today?
The FDA cleared Nasus's IND for NS002, its intranasal epinephrine powder for anaphylaxis, and the company plans a pivotal study in the fourth quarter of 2026. At 12:24 ET the stock was at $3.75, up 10.13% on the session.
What is NS002?
NS002 is a needle-free epinephrine powder given through the nose for severe allergic reactions. In Phase 2 it reached the 100 pg/mL epinephrine threshold in a median of 1.69 minutes, compared with 3.47 minutes for EpiPen.
When will Nasus Pharma report pivotal NS002 data?
Nasus plans to start the pivotal study in the fourth quarter of 2026 and expects topline data in the first quarter of 2027, which it intends to use to support a potential New Drug Application.
How much cash does Nasus Pharma have?
$11.9 million at June 30, 2026, which the company said funds operations through the second quarter of 2027.
Sources
-
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
— GlobeNewswire
FDA cleared the NS002 IND; the cleared study compares self-administration with administration by a health care professional; pivotal study planned in Q4 2026 with topline data in Q1 2027; Phase 2 median T100 of 1.69 minutes versus 3.47 minutes for EpiPen.
-
Nasus Pharma Gets FDA IND Clearance for NS002 Study
— StockTitan
Nasus Pharma received FDA clearance for an NS002 study and plans a pivotal study.
-
Nasus Pharma Targets Q4 Pivotal Study For Intranasal Epinephrine In $2 Billion Market, With Topline Data Expected Q1 2027
— Pulse 2.0
Nasus plans a Q4 2026 pivotal study of NS002 with topline data in Q1 2027 in an anaphylaxis market it estimates at about $2 billion.
Never miss the next market-moving story
Follow the core market-moving feed across equities, macro, currencies and commodities. Your subscription includes recorded price reactions, search, watchlists, alerts and research tools.
Start Pro Watch live headlines -- free